193 related articles for article (PubMed ID: 23912960)
1. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.
Botteri E; Munzone E; Rotmensz N; Cipolla C; De Giorgi V; Santillo B; Zanelotti A; Adamoli L; Colleoni M; Viale G; Goldhirsch A; Gandini S
Breast Cancer Res Treat; 2013 Aug; 140(3):567-75. PubMed ID: 23912960
[TBL] [Abstract][Full Text] [Related]
2. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
3. β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients.
Song HJ; Lee J; Kim YJ; Jung SY; Kim HJ; Choi NK; Park BJ
Bone; 2012 Dec; 51(6):1008-15. PubMed ID: 22960238
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
Ma JG; Wang NJ; Yu WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.
Holmes S; Griffith EJ; Musto G; Minuk GY
Cancer Epidemiol; 2013 Dec; 37(6):881-5. PubMed ID: 24075077
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors.
Colonna SV; Higgins AK; Alvarez J; Saville BR; Lawrence J; Abramson VG
Clin Breast Cancer; 2016 Jun; 16(3):223-31. PubMed ID: 26683741
[TBL] [Abstract][Full Text] [Related]
7. Evidence of β-blockers drug repurposing for the treatment of triple negative breast cancer: A systematic review.
Spini A; Roberto G; Gini R; Bartolini C; Bazzani L; Donnini S; Crispino S; Ziche M
Neoplasma; 2019 Nov; 66(6):963-970. PubMed ID: 31607128
[TBL] [Abstract][Full Text] [Related]
8. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.
Melhem-Bertrandt A; Chavez-Macgregor M; Lei X; Brown EN; Lee RT; Meric-Bernstam F; Sood AK; Conzen SD; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2011 Jul; 29(19):2645-52. PubMed ID: 21632501
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
Munzone E; Botteri E; Sciandivasci A; Curigliano G; Nolè F; Mastropasqua M; Rotmensz N; Colleoni M; Esposito A; Adamoli L; Luini A; Goldhirsch A; Viale G
Breast Cancer Res Treat; 2012 Jul; 134(1):277-82. PubMed ID: 22467243
[TBL] [Abstract][Full Text] [Related]
10. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.
Chen X; Yu X; Chen J; Zhang Z; Tuan J; Shao Z; Guo X; Feng Y
Cancer; 2013 Jul; 119(13):2366-74. PubMed ID: 23576181
[TBL] [Abstract][Full Text] [Related]
11. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
12. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort.
Ganz PA; Habel LA; Weltzien EK; Caan BJ; Cole SW
Breast Cancer Res Treat; 2011 Sep; 129(2):549-56. PubMed ID: 21479924
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
14. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.
Assayag J; Pollak MN; Azoulay L
Eur J Cancer; 2014 Nov; 50(16):2838-45. PubMed ID: 25204805
[TBL] [Abstract][Full Text] [Related]
15. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
16. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade.
Choy C; Raytis JL; Smith DD; Duenas M; Neman J; Jandial R; Lew MW
Oncol Rep; 2016 Jun; 35(6):3135-42. PubMed ID: 27035124
[TBL] [Abstract][Full Text] [Related]
20. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
